JP2017534259A5 - - Google Patents
Download PDFInfo
- Publication number
- JP2017534259A5 JP2017534259A5 JP2017514687A JP2017514687A JP2017534259A5 JP 2017534259 A5 JP2017534259 A5 JP 2017534259A5 JP 2017514687 A JP2017514687 A JP 2017514687A JP 2017514687 A JP2017514687 A JP 2017514687A JP 2017534259 A5 JP2017534259 A5 JP 2017534259A5
- Authority
- JP
- Japan
- Prior art keywords
- seq
- amino acid
- antibody
- met
- acid sequence
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Granted
Links
- 125000003275 alpha amino acid group Chemical group 0.000 claims 53
- 239000000427 antigen Substances 0.000 claims 20
- 102000036639 antigens Human genes 0.000 claims 20
- 108091007433 antigens Proteins 0.000 claims 20
- 239000000203 mixture Substances 0.000 claims 12
- 210000004027 cell Anatomy 0.000 claims 9
- 102000057421 human MET Human genes 0.000 claims 7
- 108010066733 mRNA (guanine(N7))-methyltransferase Proteins 0.000 claims 7
- 239000002773 nucleotide Substances 0.000 claims 4
- 125000003729 nucleotide group Chemical group 0.000 claims 4
- 239000008194 pharmaceutical composition Substances 0.000 claims 3
- 230000002401 inhibitory effect Effects 0.000 claims 2
- 238000004519 manufacturing process Methods 0.000 claims 2
- 206010028980 Neoplasm Diseases 0.000 claims 1
- 150000001413 amino acids Chemical class 0.000 claims 1
- 201000011510 cancer Diseases 0.000 claims 1
- 230000015556 catabolic process Effects 0.000 claims 1
- 230000010261 cell growth Effects 0.000 claims 1
- 238000012258 culturing Methods 0.000 claims 1
- 238000006731 degradation reaction Methods 0.000 claims 1
- 208000037265 diseases, disorders, signs and symptoms Diseases 0.000 claims 1
- 230000007783 downstream signaling Effects 0.000 claims 1
- 210000002889 endothelial cell Anatomy 0.000 claims 1
- 230000012010 growth Effects 0.000 claims 1
- 238000000338 in vitro Methods 0.000 claims 1
- 238000001727 in vivo Methods 0.000 claims 1
- 230000001404 mediated effect Effects 0.000 claims 1
- 150000007523 nucleic acids Chemical class 0.000 claims 1
- 102000039446 nucleic acids Human genes 0.000 claims 1
- 108020004707 nucleic acids Proteins 0.000 claims 1
- 239000000546 pharmaceutical excipient Substances 0.000 claims 1
- 230000026731 phosphorylation Effects 0.000 claims 1
- 238000006366 phosphorylation reaction Methods 0.000 claims 1
- 230000004614 tumor growth Effects 0.000 claims 1
Applications Claiming Priority (3)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US201462051190P | 2014-09-16 | 2014-09-16 | |
| US62/051,190 | 2014-09-16 | ||
| PCT/IB2015/002110 WO2016042412A1 (en) | 2014-09-16 | 2015-09-15 | Anti-met antibodies and compositions |
Publications (3)
| Publication Number | Publication Date |
|---|---|
| JP2017534259A JP2017534259A (ja) | 2017-11-24 |
| JP2017534259A5 true JP2017534259A5 (enExample) | 2018-10-18 |
| JP6927875B2 JP6927875B2 (ja) | 2021-09-01 |
Family
ID=54780359
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2017514687A Active JP6927875B2 (ja) | 2014-09-16 | 2015-09-15 | 抗ｍｅｔ抗体および組成物 |
Country Status (11)
| Country | Link |
|---|---|
| US (1) | US10450376B2 (enExample) |
| EP (1) | EP3194444B1 (enExample) |
| JP (1) | JP6927875B2 (enExample) |
| KR (1) | KR102200274B1 (enExample) |
| CN (1) | CN107001471B (enExample) |
| AU (1) | AU2015316522B2 (enExample) |
| CA (1) | CA2961323C (enExample) |
| ES (1) | ES2748295T3 (enExample) |
| IL (1) | IL250902B (enExample) |
| MX (1) | MX378108B (enExample) |
| WO (1) | WO2016042412A1 (enExample) |
Families Citing this family (15)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| IL262869B (en) | 2016-05-17 | 2022-07-01 | Abbvie Biotherapeutics Inc | Anti-cmet antibody drug conjugates and methods for their use |
| IL265645B2 (en) * | 2016-09-29 | 2024-05-01 | Mitsubishi Tanabe Pharma Corp | Cmet monoclonal binding agents, drug conjugates thereof and uses thereof |
| TWI782930B (zh) | 2016-11-16 | 2022-11-11 | 美商再生元醫藥公司 | 抗ｍｅｔ抗體，結合ｍｅｔ之雙特異性抗原結合分子及其使用方法 |
| WO2018223958A1 (zh) | 2017-06-06 | 2018-12-13 | 江苏恒瑞医药股份有限公司 | 一种含c-Met抗体药物偶联物的药物组合物及其用途 |
| CN120586086A (zh) * | 2018-03-28 | 2025-09-05 | 田边三菱制药株式会社 | cMET单克隆结合剂的药物缀合物及其用途 |
| KR102221755B1 (ko) * | 2018-05-02 | 2021-03-02 | (주)에임드바이오 | c-Met에 특이적으로 결합하는 항체 및 그의 용도 |
| KR102433184B1 (ko) * | 2018-12-07 | 2022-08-17 | 서울대학교 산학협력단 | 항 c-Met 아고니스트 항체 및 이의 용도 |
| CA3143211A1 (en) * | 2019-06-26 | 2020-12-30 | Glaxosmithkline Intellectual Property Development Limited | Il1rap binding proteins |
| US11896682B2 (en) | 2019-09-16 | 2024-02-13 | Regeneron Pharmaceuticals, Inc. | Radiolabeled MET binding proteins for immuno-PET imaging and methods of use thereof |
| WO2021058735A1 (en) | 2019-09-26 | 2021-04-01 | Symphogen A/S | Cancer treatment with anti-met antibody compositions |
| WO2022204332A1 (en) * | 2021-03-24 | 2022-09-29 | Combangio, Inc. | Compositions comprising c-met agonist antibodies and methods for use in ocular treatment |
| KR20230166099A (ko) | 2021-04-08 | 2023-12-06 | 비온디스 비.브이. | 항-c-met 항체 및 항체-약물 접합체 |
| EP4472997A2 (en) * | 2022-02-02 | 2024-12-11 | The Broad Institute, Inc. | Targeting moieties promoting transduction of central nervous system cells and tissues and methods of use |
| CA3256012A1 (en) | 2022-05-20 | 2023-11-23 | Les Laboratoires Servier | ANTIBODY-DRUG CONJUGATES, MET INHIBITORS BCL-XL, AND THEIR METHODS OF USE |
| AR132710A1 (es) | 2023-05-19 | 2025-07-23 | Servier Lab | Anticuerpos anti-met, adc, composiciones y usos de los mismos |
Family Cites Families (59)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US5179017A (en) | 1980-02-25 | 1993-01-12 | The Trustees Of Columbia University In The City Of New York | Processes for inserting DNA into eucaryotic cells and for producing proteinaceous materials |
| US4634665A (en) | 1980-02-25 | 1987-01-06 | The Trustees Of Columbia University In The City Of New York | Processes for inserting DNA into eucaryotic cells and for producing proteinaceous materials |
| US4399216A (en) | 1980-02-25 | 1983-08-16 | The Trustees Of Columbia University | Processes for inserting DNA into eucaryotic cells and for producing proteinaceous materials |
| US4510245A (en) | 1982-11-18 | 1985-04-09 | Chiron Corporation | Adenovirus promoter system |
| US4740461A (en) | 1983-12-27 | 1988-04-26 | Genetics Institute, Inc. | Vectors and methods for transformation of eucaryotic cells |
| US5168062A (en) | 1985-01-30 | 1992-12-01 | University Of Iowa Research Foundation | Transfer vectors and microorganisms containing human cytomegalovirus immediate-early promoter-regulatory DNA sequence |
| DE3668186D1 (de) | 1985-04-01 | 1990-02-15 | Celltech Ltd | Transformierte myeloma-zell-linie und dieselbe verwendendes verfahren zur expression eines gens, das ein eukaryontisches polypeptid kodiert. |
| US4968615A (en) | 1985-12-18 | 1990-11-06 | Ciba-Geigy Corporation | Deoxyribonucleic acid segment from a virus |
| GB8601597D0 (en) | 1986-01-23 | 1986-02-26 | Wilson R H | Nucleotide sequences |
| US4959455A (en) | 1986-07-14 | 1990-09-25 | Genetics Institute, Inc. | Primate hematopoietic growth factors IL-3 and pharmaceutical compositions |
| US4912040A (en) | 1986-11-14 | 1990-03-27 | Genetics Institute, Inc. | Eucaryotic expression system |
| US5750172A (en) | 1987-06-23 | 1998-05-12 | Pharming B.V. | Transgenic non human mammal milk |
| GB8717430D0 (en) | 1987-07-23 | 1987-08-26 | Celltech Ltd | Recombinant dna product |
| GB8809129D0 (en) | 1988-04-18 | 1988-05-18 | Celltech Ltd | Recombinant dna methods vectors and host cells |
| US5223409A (en) | 1988-09-02 | 1993-06-29 | Protein Engineering Corp. | Directed evolution of novel binding proteins |
| US5959177A (en) | 1989-10-27 | 1999-09-28 | The Scripps Research Institute | Transgenic plants expressing assembled secretory antibodies |
| US5633076A (en) | 1989-12-01 | 1997-05-27 | Pharming Bv | Method of producing a transgenic bovine or transgenic bovine embryo |
| US5427908A (en) | 1990-05-01 | 1995-06-27 | Affymax Technologies N.V. | Recombinant library screening methods |
| AU665190B2 (en) | 1990-07-10 | 1995-12-21 | Cambridge Antibody Technology Limited | Methods for producing members of specific binding pairs |
| GB9015198D0 (en) | 1990-07-10 | 1990-08-29 | Brien Caroline J O | Binding substance |
| WO1992009690A2 (en) | 1990-12-03 | 1992-06-11 | Genentech, Inc. | Enrichment method for variant proteins with altered binding properties |
| DE69233769D1 (de) | 1991-03-01 | 2009-09-24 | Dyax Corp | Chimäres Protein mit Mikroprotein mit zwei oder mehr Disulfidbindungen und Ausgestaltungen davon |
| ATE269401T1 (de) | 1991-04-10 | 2004-07-15 | Scripps Research Inst | Bibliotheken heterodimerer rezeptoren mittels phagemiden |
| DE4122599C2 (de) | 1991-07-08 | 1993-11-11 | Deutsches Krebsforsch | Phagemid zum Screenen von Antikörpern |
| DE69229477T2 (de) | 1991-09-23 | 1999-12-09 | Cambridge Antibody Technology Ltd., Melbourn | Methoden zur Herstellung humanisierter Antikörper |
| JP3553936B2 (ja) | 1992-09-18 | 2004-08-11 | アメリカ合衆国 | Ｈｇｆ／ｓｆの生産およびそれに有用な細胞系 |
| EP0804070B1 (en) | 1993-03-09 | 2000-05-24 | Genzyme Corporation | Process of isolation of proteins from milk |
| US5827690A (en) | 1993-12-20 | 1998-10-27 | Genzyme Transgenics Corporatiion | Transgenic production of antibodies in milk |
| US5707624A (en) | 1994-06-03 | 1998-01-13 | The Regents Of The University Of Michigan | Treatment of Kaposi's sarcoma by inhibition of scatter factor |
| US6046037A (en) | 1994-12-30 | 2000-04-04 | Hiatt; Andrew C. | Method for producing immunoglobulins containing protection proteins in plants and their use |
| US5686292A (en) | 1995-06-02 | 1997-11-11 | Genentech, Inc. | Hepatocyte growth factor receptor antagonist antibodies and uses thereof |
| US6214344B1 (en) | 1995-06-02 | 2001-04-10 | Genetech, Inc. | Hepatocyte growth factor receptor antagonists and uses thereof |
| AU729029B2 (en) | 1996-07-03 | 2001-01-25 | Genentech Inc. | Hepatocyte growth factor receptor agonists and uses thereof |
| WO1998052976A1 (en) | 1997-05-21 | 1998-11-26 | Biovation Limited | Method for the production of non-immunogenic proteins |
| JP2002522063A (ja) | 1998-08-17 | 2002-07-23 | アブジェニックス インコーポレイテッド | 増加した血清半減期を有する改変された分子の生成 |
| CA2342967A1 (en) | 1998-12-08 | 2000-06-15 | Biovation Limited | Modifying protein immunogenicity |
| US6517529B1 (en) | 1999-11-24 | 2003-02-11 | Radius International Limited Partnership | Hemodialysis catheter |
| SI1583830T1 (sl) | 2003-01-07 | 2006-12-31 | Symphogen As | Postopek za pripravo rekombinantnih poliklonskih proteinov |
| ITMI20031127A1 (it) | 2003-06-05 | 2004-12-06 | Uni Degli Studi Del Piemont E Orientale Am | Anticorpi anti-hgf-r e loro uso |
| HN2004000285A (es) | 2003-08-04 | 2006-04-27 | Pfizer Prod Inc | ANTICUERPOS DIRIGIDOS A c-MET |
| TWI333977B (en) | 2003-09-18 | 2010-12-01 | Symphogen As | Method for linking sequences of interest |
| CA2565827A1 (en) | 2004-05-05 | 2005-12-15 | Merrimack Pharmaceuticals, Inc. | Bispecific binding agents for modulating biological activity |
| WO2006015371A2 (en) | 2004-08-05 | 2006-02-09 | Genentech, Inc. | Humanized anti-cmet antagonists |
| CA2599988A1 (en) | 2005-03-25 | 2006-10-05 | Genentech, Inc. | Methods and compositions for modulating hyperstabilized c-met |
| WO2007110698A2 (en) | 2005-11-16 | 2007-10-04 | Fariba Nayeri | Methods for inhibiting carcinogenesis and/or metastasis in an individual with endogenous c-met ligands and inhibitors |
| EP1981981B1 (en) | 2006-02-06 | 2011-06-29 | Metheresis Translational Research SA | Anti-met monoclonal antibody, fragments and vectors thereof, for the treatment of tumors and corresponding products |
| EP1997511B1 (en) | 2006-03-20 | 2011-07-20 | Seikagaku Corporation | Therapeutic agent for rheumatoid arthritis |
| WO2007126799A2 (en) | 2006-03-30 | 2007-11-08 | Novartis Ag | Compositions and methods of use for antibodies of c-met |
| US8039598B2 (en) | 2007-01-19 | 2011-10-18 | Van Andel Research Institute | Met fab and SCFV fragments |
| DE602008002593D1 (de) | 2007-05-25 | 2010-10-28 | Symphogen As | Verfahren zur herstellung eines rekombinanten polyklonalen proteins |
| EP2014681A1 (en) | 2007-07-12 | 2009-01-14 | Pierre Fabre Medicament | Novel antibodies inhibiting c-met dimerization, and uses thereof |
| US7892770B2 (en) | 2007-08-24 | 2011-02-22 | Van Andel Research Institute | Monoclonal antibody which binds cMet (HGFR) in formalin-fixed and paraffin-embedded tissues and related methods |
| KR20110016899A (ko) | 2008-04-23 | 2011-02-18 | 심포젠 에이/에스 | 폴리클로날 단백질을 제조하는 방법 |
| WO2009142738A2 (en) * | 2008-05-21 | 2009-11-26 | Oncomed Pharmaceuticals, Inc. | Compositions and methods for diagnosing and treating cancer |
| EP4083072A1 (en) * | 2008-10-06 | 2022-11-02 | Minerva Biotechnologies Corporation | Muc1* antibodies |
| PA8849001A1 (es) * | 2008-11-21 | 2010-06-28 | Lilly Co Eli | Anticuerpos de c-met |
| DK3904391T3 (en) | 2010-03-10 | 2024-10-14 | Genmab As | Monoclonal antibodies against c-met |
| MX347981B (es) | 2010-11-01 | 2017-05-22 | Symphogen As | Composicion de anticuerpos pan-her. |
| US9688773B2 (en) | 2010-11-03 | 2017-06-27 | Argen-X N.V. | C-Met antibody combinations |
-
2015
- 2015-09-15 CA CA2961323A patent/CA2961323C/en active Active
- 2015-09-15 IL IL250902A patent/IL250902B/en unknown
- 2015-09-15 US US15/510,545 patent/US10450376B2/en active Active
- 2015-09-15 KR KR1020177010306A patent/KR102200274B1/ko active Active
- 2015-09-15 ES ES15804578T patent/ES2748295T3/es active Active
- 2015-09-15 CN CN201580059801.8A patent/CN107001471B/zh active Active
- 2015-09-15 EP EP15804578.1A patent/EP3194444B1/en active Active
- 2015-09-15 MX MX2017003211A patent/MX378108B/es unknown
- 2015-09-15 AU AU2015316522A patent/AU2015316522B2/en active Active
- 2015-09-15 JP JP2017514687A patent/JP6927875B2/ja active Active
- 2015-09-15 WO PCT/IB2015/002110 patent/WO2016042412A1/en not_active Ceased
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| JP2017534259A5 (enExample) | ||
| JP2014503189A5 (enExample) | ||
| ES2662519T3 (es) | Anticuerpos neutralizantes contra el virus de la gripe A y usos de estos | |
| RU2504553C2 (ru) | Антитела к her | |
| FI3515487T3 (fi) | Bispesifisiä anti-MUC16-CD3-vasta-aineita ja anti-MUC16-lääkekonjugaatteja | |
| JP2020503001A5 (enExample) | ||
| RU2014103784A (ru) | Антитело, блокирующее agr2, и его применение | |
| RU2451689C2 (ru) | Новые антипролиферативные антитела | |
| JP2015517300A5 (enExample) | ||
| RU2012143793A (ru) | Биспецифические двухвалентные антитела анти-vegf/анти-ang-2 | |
| JP2013520984A5 (enExample) | ||
| RU2018114904A (ru) | Антитело против garp | |
| JP2017532005A5 (enExample) | ||
| IL273841B1 (en) | Antibodies targeting cd137 and methods of use thereof | |
| FI3137504T3 (fi) | Fcrn:ään sitoutuva vasta-aine autoimmuunisairauksien hoitamista varten | |
| RU2013104830A (ru) | Лечение рака при помощи направленных на мишень антител in vivo | |
| RU2017107773A (ru) | Антитела, специфичные к ммр9 | |
| RU2012131411A (ru) | АНТИТЕЛА ПРОТИВ Bv8 И ИХ ПРИМЕНЕНИЕ | |
| RU2016107814A (ru) | Новое антитело к tslp-рецептору человека | |
| US12252539B2 (en) | Anti-FLT3 antibodies and compositions | |
| IL273578B1 (en) | Antibodies targeting pdl1 and methods of use thereof | |
| JP2010509931A5 (enExample) | ||
| JP2015530989A5 (enExample) | ||
| JP2016520595A5 (enExample) | ||
| JP2014532706A5 (enExample) |